Nanoparticles Delivers Promising Results in Developing Anti-Cancer Activity

Release Date: 12-Nov-2020

Cancer now-a-days by the researchers working at the University of Southern California are conducting researchers at the nano-scale. The group of researchers working at the respective university have developed a nanoparticle micelle that can target specifically cancer cells. In the current therapeutics industry, researchers as well as physicians are getting huge challenges with respect to the growing demand of the cancer patients. Among all the challenges, one of the most complex challenges ever come across by the researchers is the chance of cancer recurrence as well as cancer metastasis.


The therapeutic development of nanoparticles is estimated to be efficient and promising with respect to all the other old and traditional cancer therapies. The nanoparticle micelle developed by the researchers is a nano-sized sphere which is labelled with monocyte chemoattractant protein-1 (MCP-1) chemokine on its surface. Monocyte chemoattractant protein-1 (MCP-1) chemokine is observed to be highly expressed within the tumors, also it is observed to be promoting the cancer disease progression and development.


Other than this, the overall secretion of MCP-1 and its further interaction with CCR2 also leads to the gathering of the cell population that is observed to be suppressing the immune response of the patients against the cancer cells. Therefore, the binding of micelle with MCP-1 peptide will lead to interaction with specific cancer cells further leading to the inhibition of encroachment of the cell population that can suppress the immune system against the cancer cells.


Also, the introduction of the micelle with another drug called as KLAKKLAK which is cytotoxic to cancer cells is estimated to minimize the cytotoxicity to other healthy cells neighbouring the cancer cells. When the same hypothesis was tested in in-vivo, it was found that nanoparticles were able to reduce the volume of tumor. Also, the same led to an increase in the infiltration of TCL at the site of tumor, thus leading to enhancement of the therapeutic efficiency in the patients.


The generation of immune response the cancer cells by the patients with the help of nanoparticles is estimated to go long way to cause a decline in the cancer mortality. The researchers working on the clinical research study are also inclined towards applying similar idea of peptide-based targeting of the cancer in other types of cancers too. In addition to this, the variation in the expression of CCR2 is also estimated to be strong anti-cancer effect when aligned with micelle.

Need custom market research solution? We can help you with that too.